Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 4.5% – Should You Sell?

Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) fell 4.5% during mid-day trading on Thursday . The stock traded as low as $0.31 and last traded at $0.32. 28,860,322 shares changed hands during mid-day trading, a decline of 7% from the average session volume of 31,034,150 shares. The stock had previously closed at $0.33.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on Tonix Pharmaceuticals in a report on Wednesday. They set a “hold” rating for the company.

Tonix Pharmaceuticals Stock Performance

The stock’s fifty day simple moving average is $0.24 and its 200-day simple moving average is $0.36. The company has a market capitalization of $57.94 million, a price-to-earnings ratio of -0.01 and a beta of 2.02. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The business had revenue of $2.82 million for the quarter, compared to analysts’ expectations of $2.63 million. Analysts predict that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.